| Description | TTA-Q6 is a selective T-type Ca2+ channel antagonist with potential antitumor and immunomodulatory activity for the treatment of neurological disorders by inhibiting the uptake of extracellular calcium ions by tumor cells and inducing intracellular calcium deficiency and endoplasmic reticulum (ER) stress. |
| In vitro | 在肿瘤酸性环境中，TTA-Q6 被释放，破坏癌细胞钙的摄取，引起内质网应激并诱导钙网蛋白转移到细胞表面[1]。 |
| molecular weight | 405.8 |
| Molecular formula | C20H15ClF3N3O |
| CAS | 910484-28-5 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 100 mg/mL (246.43 mM), Sonication is recommended. |
| References | 1. Guo Y,et al. Nanomedicine-based co-delivery of a calcium channel inhibitor and a small molecule targeting CD47 for lung cancer immunotherapy. Nat Commun. 2023 Nov 11;14(1):7306. |